The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Persistence of Increased Cardiovascular Risk in Patients with Cushing's Disease after Five Years of Successful Cure
Abstract
Patients with Cushing's disease (CD) mainly die because of cardiovascular accidents. The aim of this study was to evaluate whether patients with CD still have increased cardiovascular risk and suffer from premature atherosclerosis once cured. Fifteen patients cured from CD for a long term period (5 yr), 30 sex-and age-matched controls, and 30 body mass index (BMI)-matched controls were included in this study. BMI; waist to hip ratio (WHR); systolic (SBP) and diastolic (DBP) blood pressures; serum total, low density lipoprotein (LDL), and high density lipoprotein (HDL) cholesterol; serum triglycerides, fibrinogen, and lipoprotein(a) levels; prothrombin time; activated partial thromboplastine time; and basal and glucose load-stimulated insulin and glucose levels were measured in patients and controls. By echo-Doppler ultrasonography, the intima media thickness (IMT), systolic and diastolic media-media distances, blood systolic (SPV) and diastolic (DPV) peak velocity, systolic (SLD) and diastolic (DLD) lumen diameter, and distensibility coefficient (DC) were measured at both common carotid arteries where the presence, size, and location of atherosclerotic plaques were also evaluated. Compared with a sex- and age-matched control population, CD patients had BMI (P < 0.001), WHR (P < 0.001), SBP (P < 0.005), DBP (P < 0.05), fasting glucose (P < 0.001) and insulin (P < 0.05), glucose load-stimulated glucose and insulin levels (P < 0.05), total cholesterol (P < 0.05), LDL cholesterol (P < 0.01), fibrinogen (P < 0.01), and lipoprotein(a) (P < 0.05) levels higher and HDL cholesterol levels (P < 0.05) lower than controls. At ultrasonography, in the patients, IMT (P < 0.05), SPV (P < 0.05) and DPV (P < 0.001) were significantly increased whereas SLD (P < 0.001), DLD (P < 0.001), and DC (P < 0.05) were significantly decreased compared to controls. In addition, CD patients had higher WHR (P < 0.05), DBP (P < 0.05), glucose load-stimulated glucose and insulin levels (P < 0.05), and fibrinogen levels (P < 0.01) and lower HDL cholesterol (P < 0.05) levels than BMI-matched controls. At ultrasonography, increased common carotid arteries IMT (P < 0.05) and DPV (P < 0.05) and decreased DLD (P < 0.05) and DC (P < 0.05) were measured in patients compared to those in BMI-matched controls. Atherosclerotic plaques were found in 26.7% of patients, in none of the sex- and age-matched controls, and in 3.3% of the BMI-matched controls. In CD patients, a significant correlation was found between both WHR and fasting serum insulin levels and DBP (r = 0.52 and r = 0.55; P < 0.05), triglycerides levels (r = 0.56 and r = 0.77; P < 0.05), and IMT (r = 0.64 and r = 0.56; P < 0.05). Right (r = -0.70; P < 0.005) and left (r = -0.65; P < 0.01) DC were inversely correlated to the duration of CD in the patient group. At the multiple regression analysis, WHR was the best predictor of fasting insulin levels (beta = 0.77; P < 0.05), and vice versa, fasting insulin level was the best predictor of WHR (beta = 1.20; P < 0.05). In conclusion, patients cured from CD for a long term period have a high prevalence of atherosclerosis and maintain increased several cardiovascular risk factors of the active disease, probably due to a residual abdominal obesity and/or insulin resistance syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Williams Textbook of Endocrinology
(2016) · Elsevier eBooks · doi:10.1016/c2013-0-15980-6 · Cited by 3,711
Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging.
Pignoli, P., Tremoli, E., Poli, A., Oreste, P., & Paoletti, R. (1986) · Circulation · doi:10.1161/01.cir.74.6.1399 · Cited by 2,404
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,246
Ohlson, L. O., Larsson, B., Svärdsudd, K., Welin, L., Eriksson, H., Wilhelmsen, L., Björntorp, P., & Tibblin, G. (1985) · Diabetes · doi:10.2337/diab.34.10.1055 · Cited by 1,020
The natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763
; (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.2.379 · Cited by 655
Morbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622
Lipoprotein (a). Heterogeneity and biological relevance.
Scanu, A. M., & Fless, G. M. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114625 · Cited by 573
[WHO Expert Committee on diabetes mellitus].
Reitsma, W. D., & Terpstra, J. (1981) · PubMed · Cited by 556
Cited by
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
“Because markers of cardiovascular risk remain abnormal for up to 5 yr after surgery, further studies are needed to assess long-term SMR (14).”
BackgroundInfluentialLacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Sgk1-Dependent Stimulation of Cardiac Na+/H+Exchanger Nhe1 by Dexamethasone
Voelkl, J., Pasham, V., Ahmed, M. S. E., Walker, B., Szteyn, K., Kuhl, D., Metzler, B., Alesutan, I., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350120 · Cited by 857
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730
Is visceral obesity the cause of the metabolic syndrome?
Després, J. (2006) · Annals of Medicine · doi:10.1080/07853890500383895 · Cited by 651
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Self-citationIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619
The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis
Anagnostis, P., Athyros, V. G., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0370 · Cited by 613
Association of depression with medical illness: Does cortisol play a role?
Brown, E. S., Varghese, F. P., & McEwen, B. S. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00473-6 · Cited by 578
Glucocorticoids and cardiovascular disease
Walker, B. R. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0455 · Cited by 529
Depression and cardiovascular disease: mechanisms of interaction
Joynt, K. E., Whellan, D. J., & O'Connor, C. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00568-7 · Cited by 507
Souverein, P. C., Berard, A., Van Staa, T. P., Cooper, C., Egberts, A. C. G., Leufkens, H. G. M., & Walker, B. R. (2004) · Heart · doi:10.1136/hrt.2003.020180 · Cited by 482
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Self-citationMultisystem morbidity and mortality in Cushing’s syndrome: a cohort study
Dekkers, O. M., Horváth-Puhó, E., Jørgensen, J. O. L., Cannegieter, S. C., Ehrenstein, V., Vandenbroucke, J. P., Pereira, A. M., & Sørensen, H. T. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3582 · Cited by 419
Tauchmanovà, L., Rossi, R., Biondi, B., Pulcrano, M., Nuzzo, V., Palmieri, E.-A., Fazio, S., & Lombardi, G. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011766 · Cited by 400
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Cardiovascular consequences of cortisol excess
Whitworth, J. A., Williamson, P. M., Mangos, G., & Kelly, J. J. (2005) · Vascular Health and Risk Management · doi:10.2147/vhrm.2005.1.4.291 · Cited by 392
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Clayton, R. N., Raskauskiene, D., Reulen, R. C., & Jones, P. W. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1942 · Cited by 374
Faggiano, A., Pivonello, R., Spiezia, S., De Martino, M. C., Filippella, M., Di Somma, C., Lombardi, G., & Colao, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021558 · Cited by 358
Self-citationMIF: a new cytokine link between rheumatoid arthritis and atherosclerosis
Morand, E. F., Leech, M., & Bernhagen, J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2029 · Cited by 351
High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines
Mancini, T., Kola, B., Mantero, F., Boscaro, M., & Arnaldi, G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02168.x · Cited by 278
Orio, F., Palomba, S., Spinelli, L., Cascella, T., Tauchmanovà, L., Zullo, F., Lombardi, G., & Colao, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032049 · Cited by 275
Self-citationDopamine Receptor Expression and Function in Corticotroph Pituitary Tumors
Pivonello, R., Ferone, D., de Herder, W. W., Kros, J. M., Del Basso De Caro, M. L., Arvigo, M., Annunziato, L., Lombardi, G., Colao, A., Hofland, L. J., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030837 · Cited by 271
Self-citationFeelders, R. A., Pulgar, S. J., Kempel, A., & Pereira, A. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1095 · Cited by 256
Cushing's disease: pathobiology, diagnosis, and management
Lonser, R. R., Nieman, L., & Oldfield, E. H. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152119 · Cited by 215
Cushing's syndrome: epidemiology and developments in disease management
Feelders, R., Sharma, S., & Nieman, L. (2015) · Clinical Epidemiology · doi:10.2147/clep.s44336 · Cited by 210
Diabetes in Cushing syndrome: basic and clinical aspects
Mazziotti, G., Gazzaruso, C., & Giustina, A. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.001 · Cited by 193
Pivonello, R., De Martino, M. C., De Leo, M., Lombardi, G., & Colao, A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.010 · Cited by 195
Self-citationDoes altered glucocorticoid homeostasis increase cardiovascular risk?
GIROD, J., & BROTMAN, D. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.07.006 · Cited by 193
Subclinical Cushing’s syndrome in adrenal incidentalomas
Terzolo, M., Bovio, S., Reimondo, G., Pia, A., Osella, G., Borretta, G., & Angeli, A. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.008 · Cited by 179
Mortality and morbidity in Cushing's syndrome in New Zealand
Bolland, M. J., Holdaway, I. M., Berkeley, J. E., Lim, S., Dransfield, W. J., Conaglen, J. V., Croxson, M. S., Gamble, G. D., Hunt, P. J., & Toomath, R. J. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04124.x · Cited by 182
The Metabolic Syndrome and Cardiovascular Risk in Cushing's Syndrome
Pivonello, R., Faggiano, A., Lombardi, G., & Colao, A. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.010 · Cited by 173
Self-citationGlucocorticoids and Type 2 Diabetes: From Physiology to Pathology
Di Dalmazi, G., Pagotto, U., Pasquali, R., & Vicennati, V. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/525093 · Cited by 168
Andela, C. D., van Haalen, F. M., Ragnarsson, O., Papakokkinou, E., Johannsson, G., Santos, A., Webb, S. M., Biermasz, N. R., van der Wee, N. J. A., & Pereira, A. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1101 · Cited by 164
Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment
van der Pas, R., Leebeek, F. W. G., Hofland, L. J., de Herder, W. W., & Feelders, R. A. (2013) · Clinical Endocrinology · doi:10.1111/cen.12094 · Cited by 162
Subtle cognitive impairments in patients with long-term cure of Cushing’s disease
Tiemensma, J., Kokshoorn, N. E., Biermasz, N. R., Keijser, B.-J. S. A., Wassenaar, M. J. E., Middelkoop, H. A. M., Pereira, A. M., & Romijn, J. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2032 · Cited by 159
Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years
Hassan-Smith, Z. K., Sherlock, M., Reulen, R. C., Arlt, W., Ayuk, J., Toogood, A. A., Cooper, M. S., Johnson, A. P., & Stewart, P. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2957 · Cited by 153
Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up
Ntali, G., Asimakopoulou, A., Siamatras, T., Komninos, J., Vassiliadi, D., Tzanela, M., Tsagarakis, S., Grossman, A. B., Wass, J. A. H., & Karavitaki, N. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0569 · Cited by 149
Resmini, E., Minuto, F., Colao, A., & Ferone, D. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0112-9 · Cited by 147
“The persistence of a metabolic syndrome, vascular damage, and atherosclerotic plaques after cortisol level normalization keeps these subjects still at high cardiovascular risk [28, 31].”
BackgroundSelf-citationGlucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
Resmini, E., Santos, A., Gómez-Anson, B., Vives, Y., Pires, P., Crespo, I., Portella, M. J., de Juan-Delago, M., Barahona, M.-J., & Webb, S. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2231 · Cited by 133
Giordano, R., Picu, A., Marinazzo, E., D’Angelo, V., Berardelli, R., Karamouzis, I., Forno, D., Zinnà, D., Maccario, M., Ghigo, E., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04055.x · Cited by 122
Attanasio, A. F., Mo, D., Erfurth, E. M., Tan, M., Ho, K. Y., Kleinberg, D., Zimmermann, A. G., & Chanson, P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1326 · Cited by 115
Cardiovascular risk in Cushing’s syndrome
Arnaldi, G., Mancini, T., Polenta, B., & Boscaro, M. (2004) · Pituitary · doi:10.1007/s11102-005-1172-7 · Cited by 103
“All these associated abnormalities determine an increased cardiovascular risk not only during the active phase of the disease but also long after the “biomedical remission” [2].”
Backgroundvan Haalen, F. M., Broersen, L. H. A., Jorgensen, J. O., Pereira, A. M., & Dekkers, O. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0556 · Cited by 103
Wagenmakers, M. A. E. M., Netea-Maier, R. T., Prins, J. B., Dekkers, T., den Heijer, M., & Hermus, A. R. M. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0308 · Cited by 101
A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome
Valassi, E., Crespo, I., Gich, I., Rodríguez, J., & Webb, S. M. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04424.x · Cited by 91
Cushing's syndrome: aftermath of the cure
Pivonello, R., De Martino, M. C., De Leo, M., Tauchmanovà, L., Faggiano, A., Lombardi, G., & Colao, A. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800025 · Cited by 85
Self-citationSereg, M., Szappanos, Á., Tőke, J., Karlinger, K., Feldman, K., Kaszper, É., Varga, I., Gláz, E., Rácz, K., & Tóth, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0707 · Cited by 81
Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism?
Giordano, C., Guarnotta, V., Pivonello, R., Amato, M. C., Simeoli, C., Ciresi, A., Cozzolino, A., & Colao, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0754 · Cited by 79
Self-citationSubclinical Cushing's syndrome.
Terzolo, M., Reimondo, G., Bovio, S., & Angeli, A. (2004) · Pituitary · doi:10.1007/s11102-005-4024-6 · Cited by 80
Hypopituitarism and mortality in pituitary adenoma
Lindholm, J., Nielsen, E. H., Bjerre, P., Christiansen, J. S., Hagen, C., Juul, S., Jørgensen, J., Kruse, A., Laurberg, P., & Stochholm, K. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02545.x · Cited by 68
Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission
Schernthaner-Reiter, M. H., Siess, C., Gessl, A., Scheuba, C., Wolfsberger, S., Riss, P., Knosp, E., Luger, A., & Vila, G. (2019) · Endocrine · doi:10.1007/s12020-018-1819-6 · Cited by 60
Mortality in Cushing’s Disease
Clayton, R. N. (2010) · Neuroendocrinology · doi:10.1159/000315813 · Cited by 58
Cardiovascular risk and mortality in patients with active and treated hypercortisolism
Li, D., El Kawkgi, O. M., Henriquez, A. F., & Bancos, I. (2020) · Gland Surgery · doi:10.21037/gs.2019.11.03 · Cited by 42
Carroll, T. B., Javorsky, B. R., & Findling, J. W. (2016) · Endocrine Practice · doi:10.4158/ep161380.or · Cited by 41
Baroni, M. G., Giorgino, F., Pezzino, V., Scaroni, C., & Avogaro, A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0404-6 · Cited by 41
Danet‐Lamasou, M., Asselineau, J., Perez, P., Vivot, A., Nunes, M., Loiseau, H., San‐Galli, F., Cherifi‐Gatta, B., Corcuff, J., & Tabarin, A. (2015) · Clinical Endocrinology · doi:10.1111/cen.12534 · Cited by 39
Significant GH deficiency after long-term cure by surgery in adult patients with Cushing’s disease
Pecori Giraldi, F., Andrioli, M., De Marinis, L., Bianchi, A., Giampietro, A., De Martin, M., Sacco, E., Scacchi, M., Pontecorvi, A., & Cavagnini, F. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02329 · Cited by 35
“Indeed, GH deficiency impairs catch-up growth in short children cured from Cushing’s disease and treatment with GH has proven greatly beneficial in these patients (6, 7). In adults, GH deficiency could contribute to metabolic derangements, increased cardiovascular risk and osteoporosis, which have been observed years…”
BackgroundVogel, F., Braun, L., Zopp, S., Nowak, E., Schreiner, J., Benz, I., Rubinstein, G., Künzel, H., Ritzel, K., Kroiss, M., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad041 · Cited by 28
Syndromes de Cushing : physiopathologie, étiologie et principes thérapeutiques
Chabre, O. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.02.001 · Cited by 21
Metadata
- Authors
- Colao, A.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-08-01
- Volume
- 84
- Issue
- 8
- Pages
- 2664-2672
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W1995365748
- Cited by
- 450
- References
- 38
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.